Harnessing natural killer cells for refractory/relapsed non-Hodgkin lymphoma: biological roles, clinical trials, and future prospective
Biomark Res. 2024 Jul 17;12(1):66. doi: 10.1186/s40364-024-00610-z. ABSTRACT Non-Hodgkin lymphomas (NHLs) are heterogeneous and are among the most common hematological malignancies worldwide. Despite the advances …